Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Pullen

Showing results (51-60 of 69) with videos related to

Pageof 7
Sort By:
Cellular and Molecular Gastroenterology and Hepatology|December 19, 2022
Hepatocyte Smoothened Activity Controls Susceptibility to Insulin Resistance and Nonalcoholic Fatty Liver DiseaseTianyi Chen, George Dalton, Seh-Hoon Oh, et al.
Journal of Medicinal Chemistry|May 11, 2013
Discovery of potent, selective chymase inhibitors via fragment linking strategiesSteven J Taylor, Anil K Padyana, Asitha Abeywardane, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 6, 2016
A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 RatCarine M Boustany-Kari, Paul C Harrison, Hongxing Chen, et al.
JCI Insight|September 13, 2022
Pharmacological TRPC6 inhibition improves survival and muscle function in mice with Duchenne muscular dystrophyBrian L Lin, Joseph Y Shin, William Pd Jeffreys, et al.
The Journal of Clinical Investigation|October 15, 2021
The key role of NLRP3 and STING in APOL1-associated podocytopathyJunnan Wu, Archana Raman, Nathan J Coffey, et al.
Bioorganic & Medicinal Chemistry Letters|December 30, 2008
Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug designBrian N Cook, Jörg Bentzien, Andre White, et al.
Nature Communications|March 29, 2025
Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunctionKuo Du, David S Umbaugh, Liuyang Wang, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2007
Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitorsRoger J Snow, Asitha Abeywardane, Scot Campbell, et al.
Bioorganic & Medicinal Chemistry Letters|September 30, 2008
Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole leadKevin J Moriarty, Michael Winters, Lei Qiao, et al.
Bioorganic & Medicinal Chemistry Letters|July 8, 2011
Benzimidazolone as potent chymase inhibitor: modulation of reactive metabolite formation in the hydrophobic (P1) regionHo Yin Lo, Peter A Nemoto, Jin Mi Kim, et al.
Pageof 7

Showing results (51-60 of 69) with videos related to

Sort By:
Pageof 7
Cellular and Molecular Gastroenterology and Hepatology|December 19, 2022
Hepatocyte Smoothened Activity Controls Susceptibility to Insulin Resistance and Nonalcoholic Fatty Liver DiseaseTianyi Chen, George Dalton, Seh-Hoon Oh, et al.
Journal of Medicinal Chemistry|May 11, 2013
Discovery of potent, selective chymase inhibitors via fragment linking strategiesSteven J Taylor, Anil K Padyana, Asitha Abeywardane, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 6, 2016
A Soluble Guanylate Cyclase Activator Inhibits the Progression of Diabetic Nephropathy in the ZSF1 RatCarine M Boustany-Kari, Paul C Harrison, Hongxing Chen, et al.
JCI Insight|September 13, 2022
Pharmacological TRPC6 inhibition improves survival and muscle function in mice with Duchenne muscular dystrophyBrian L Lin, Joseph Y Shin, William Pd Jeffreys, et al.
The Journal of Clinical Investigation|October 15, 2021
The key role of NLRP3 and STING in APOL1-associated podocytopathyJunnan Wu, Archana Raman, Nathan J Coffey, et al.
Bioorganic & Medicinal Chemistry Letters|December 30, 2008
Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug designBrian N Cook, Jörg Bentzien, Andre White, et al.
Nature Communications|March 29, 2025
Targeting senescent hepatocytes for treatment of metabolic dysfunction-associated steatotic liver disease and multi-organ dysfunctionKuo Du, David S Umbaugh, Liuyang Wang, et al.
Bioorganic & Medicinal Chemistry Letters|May 15, 2007
Hit-to-lead studies on benzimidazole inhibitors of ITK: discovery of a novel class of kinase inhibitorsRoger J Snow, Asitha Abeywardane, Scot Campbell, et al.
Bioorganic & Medicinal Chemistry Letters|September 30, 2008
Itk kinase inhibitors: initial efforts to improve the metabolical stability and the cell activity of the benzimidazole leadKevin J Moriarty, Michael Winters, Lei Qiao, et al.
Bioorganic & Medicinal Chemistry Letters|July 8, 2011
Benzimidazolone as potent chymase inhibitor: modulation of reactive metabolite formation in the hydrophobic (P1) regionHo Yin Lo, Peter A Nemoto, Jin Mi Kim, et al.
Pageof 7